GLP-1 medicines with ulcerative colitis: what stable-disease studies can answer

Having ulcerative colitis does not turn a GLP-1 medicine for obesity or diabetes into a treatment for UC. Observational studies include people with both conditions, but they do not establish that GLP-1 medicines induce UC remission or that a result in stable disease applies during a flare. The prescribing clinician and the clinician managing UC should be clear about which condition is being treated and who will assess new symptoms.¹²³⁴

Start with the disease status, not a general safety claim

A study of people with stable inflammatory bowel disease cannot answer the same question as a study enrolling people with active symptoms. The 2026 target-trial emulation used existing health records and selected people with stable disease, based on prior treatment and utilization. It included both UC and Crohn’s disease. Its overall relapse estimates combine the two diagnoses and should not be presented as UC-only rates.¹

Another observational cohort examined people with inflammatory bowel disease and type 2 diabetes. In the UC subgroup, use of GLP-1 analogs was associated with a lower rate of a combined clinical outcome in its adjusted analysis. That result was not from random assignment and did not measure endoscopic remission. A combined outcome built from treatments and care events cannot establish what happened inside the colon or whether a particular symptom has a specific cause.²

Keep two kinds of follow-up visible

Diarrhea, nausea and abdominal symptoms can be reported with a GLP-1 medicine, and diarrhea, pain and rectal bleeding can be features of UC. That overlap is a reason to document what changed, not to assign the cause yourself. For new bleeding or worsening bowel symptoms, contact the clinician managing your UC promptly rather than assuming a medicine explains them. Get emergency care for severe abdominal pain or rectal bleeding that does not stop. Bring the exact product, the symptom history and the current UC care plan.³⁴

When apparently different study results can both be accurate

One study uses a definition of relapse in a stable, mixed inflammatory bowel disease population. The other reports a combined course of care for people with inflammatory bowel disease and type 2 diabetes and separately analyzes UC. A difference in prescriptions or health care use is not interchangeable with a report of symptoms or an endoscopic finding. These studies can inform a discussion about treatment alongside established UC care even if their headline estimates do not line up. Before applying either one, check who was enrolled, what the comparator was and what the authors counted as an event.¹²

For a consultation, an existing gastroenterology note or a summary of recent changes is more useful than a headline saying GLP-1 medicines help or hurt IBD. It lets the team ask a question that fits your current care.¹⁴

If a weight management program proposes treatment, ask what information it needs from gastroenterology before the decision and how the two teams will exchange updates. The useful question is whether the program can follow its own goal without losing sight of the disease the gastroenterology team already manages.¹³⁴